On April 2, 2019, Eli Lilly and Company (“Lilly”) filed a Petition for Post-Grant Review (“PGR”) of Genentech’s U.S. Patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Genentech
-
-
We previously wrote about Genentech’s U.S. Patent No. 6,407,213 (“the ’213 patent”) to Carter, first in October 2017, and more...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Recently, Pfizer was denied institution of two follow-on inter partes review (IPR) petitions, IPR Nos. 2018-00330 and 2018-00331 (“the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a host of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a number of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Patent Trial and Appeal Board (“the Board”) has decided not to institute inter partes review (“IPR”) on two patents owned by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]